Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S2W-21270 · Session 2

Further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005 and if it is the responsibility of the Scottish Medicines C…

Answered Asked by Alex Neil SNP Lodged 30 Nov 2005

The question

To ask the Scottish Executive, further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005 and if it is the responsibility of the Scottish Medicines Corsortium to advise the NHS on the suitability of medicines, why it is the responsibility of NHS Quality Improvement Scotland to advise NHS Scotland on the implications of the guidance from the National Institute for Clinical Excellence resulting from its consultation document, Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine.

The answer

Answered by Andy Kerr on 12 Dec 2005 · 12 days after it was lodged, on time

The Scottish Medicines Consortium (SMC) advises NHSScotland on the clinical and cost effectiveness of all new medicines, formulations and indications at, or as soon as possible after, the time of launch of a medicine. National Institute for Health and Clinical Excellence (NICE) appraisals (multiple technology appraisals) are conducted over a longer period of time, have access to more evidence beyond that which was available at the time of launch of a medicine, and are able to undertake more detailed appraisal of a medicine. Consequently the SMC process and the NICE multiple technology appraisal process should be seen as complementary processes rather than as alternatives.
NHS Quality Improvement Scotland (NHS QIS) provides the secretariat and other inputs, such as health economics, to the Scottish Medicines Consortium (SMC). SMC, however, is an autonomous body constituted by the Area Drug and Therapeutics Committees (ADTCs) of NHS boards in Scotland.

In the Official Report

No contribution in the Official Report cites S2W-21270 by reference.